- Home
- CRON vs RARE Comparison
CRON vs RARE Comparison
Compare CRON & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | RARE |
|---|---|---|
| Founded | N/A | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CRON | RARE |
|---|---|---|
| Price | $3.23 | $15.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $26.79 |
| AVG Volume (30 Days) | 757.9K | ★ 5.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 0.12 | N/A |
| Revenue | $146,587,000.00 | ★ $673,000,000.00 |
| Revenue This Year | $46.73 | $13.42 |
| Revenue Next Year | $23.43 | $31.52 |
| P/E Ratio | $26.83 | ★ N/A |
| Revenue Growth | ★ 24.63 | 20.13 |
| 52 Week Low | $2.28 | $12.73 |
| 52 Week High | $3.61 | $39.89 |
Technical Indicators
Market Signals| Indicator | CRON | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 42.71 |
| Support Level | $2.65 | $13.81 |
| Resistance Level | $3.28 | $15.81 |
| Average True Range (ATR) | 0.09 | 0.79 |
| MACD | -0.02 | 0.50 |
| Stochastic Oscillator | 23.03 | 66.91 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.